Literature DB >> 26631742

In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-Glycoprotein and Breast Cancer Resistance Protein: Part I: A Cross-Laboratory Comparison of Transporter-Protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cells.

Matthew D Harwood1, Brahim Achour2, Sibylle Neuhoff2, Matthew R Russell2, Gordon Carlson2, Geoffrey Warhurst2.   

Abstract

Over the last 5 years the quantification of transporter-protein absolute abundances has dramatically increased in parallel to the expanded use of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetics (PBPK)-linked models, for decision-making in pharmaceutical company drug development pipelines and regulatory submissions. Although several research groups have developed laboratory-specific proteomic workflows, it is unclear if the large range of reported variability is founded on true interindividual variability or experimental variability resulting from sample preparation or the proteomic methodology used. To assess the potential for methodological bias on end-point abundance quantification, two independent laboratories, the University of Manchester (UoM) and Bertin Pharma (BPh), employing different proteomic workflows, quantified the absolute abundances of Na/K-ATPase, P-gp, and breast cancer resistance protein (BCRP) in the same set of biologic samples from human intestinal and Caco-2 cell membranes. Across all samples, P-gp abundances were significantly correlated (P = 0.04, Rs = 0.72) with a 2.4-fold higher abundance (P = 0.001) generated at UoM compared with BPh. There was a systematically higher BCRP abundance in Caco-2 cell samples quantified by BPh compared with UoM, but not in human intestinal samples. Consequently, a similar intestinal relative expression factor (REF), derived from distal jejunum and Caco-2 monolayer samples, between laboratories was found for P-gp. However, a 2-fold higher intestinal REF was generated by UoM (2.22) versus BPh (1.11). We demonstrate that differences in absolute protein abundance are evident between laboratories and they probably result from laboratory-specific methodologies relating to peptide choice.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26631742     DOI: 10.1124/dmd.115.067371

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  14 in total

1.  Toward a Consensus on Applying Quantitative Liquid Chromatography-Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper.

Authors:  Bhagwat Prasad; Brahim Achour; Per Artursson; Cornelis E C A Hop; Yurong Lai; Philip C Smith; Jill Barber; Jacek R Wisniewski; Daniel Spellman; Yasuo Uchida; Michael A Zientek; Jashvant D Unadkat; Amin Rostami-Hodjegan
Journal:  Clin Pharmacol Ther       Date:  2019-07-26       Impact factor: 6.875

2.  Strategies of Drug Transporter Quantitation by LC-MS: Importance of Peptide Selection and Digestion Efficiency.

Authors:  Buyun Chen; Liling Liu; Hoangdung Ho; Yuan Chen; Ze Yang; Xiaorong Liang; Jian Payandeh; Brian Dean; Cornelis E C A Hop; Yuzhong Deng
Journal:  AAPS J       Date:  2017-06-06       Impact factor: 4.009

Review 3.  Critical Issues and Optimized Practices in Quantification of Protein Abundance Level to Determine Interindividual Variability in DMET Proteins by LC-MS/MS Proteomics.

Authors:  Deepak Kumar Bhatt; Bhagwat Prasad
Journal:  Clin Pharmacol Ther       Date:  2017-09-25       Impact factor: 6.875

4.  Ultrasensitive Quantification of Drug-metabolizing Enzymes and Transporters in Small Sample Volume by Microflow LC-MS/MS.

Authors:  Deepak Suresh Ahire; Abdul Basit; Matthew Karasu; Bhagwat Prasad
Journal:  J Pharm Sci       Date:  2021-03-28       Impact factor: 3.784

5.  Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis.

Authors:  Howard J Burt; Arian Emami Riedmaier; Matthew D Harwood; H Kim Crewe; Katherine L Gill; Sibylle Neuhoff
Journal:  Drug Metab Dispos       Date:  2016-08-04       Impact factor: 3.922

6.  Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer.

Authors:  Hongsheng Tang; Lisi Zeng; Jiahong Wang; Xiangliang Zhang; Qiang Ruan; Jin Wang; Shuzhong Cui; Dinghua Yang
Journal:  Oncotarget       Date:  2017-09-06

7.  Database of Optimized Proteomic Quantitative Methods for Human Drug Disposition-Related Proteins for Applications in Physiologically Based Pharmacokinetic Modeling.

Authors:  M Vrana; D Whittington; V Nautiyal; B Prasad
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-04-04

8.  Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction.

Authors:  Shinji Yamazaki; Chester Costales; Sarah Lazzaro; Soraya Eatemadpour; Emi Kimoto; Manthena V Varma
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-09-05

9.  Rifampicin Induces Gene, Protein, and Activity of P-Glycoprotein (ABCB1) in Human Precision-Cut Intestinal Slices.

Authors:  Ondrej Martinec; Carin Biel; Inge A M de Graaf; Martin Huliciak; Koert P de Jong; Frantisek Staud; Filip Cecka; Peter Olinga; Ivan Vokral; Lukas Cerveny
Journal:  Front Pharmacol       Date:  2021-06-09       Impact factor: 5.810

10.  Differences in P-glycoprotein activity in human and rodent blood-brain barrier assessed by mechanistic modelling.

Authors:  Laurens F M Verscheijden; Jan B Koenderink; Saskia N de Wildt; Frans G M Russel
Journal:  Arch Toxicol       Date:  2021-07-15       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.